BlackRock’s Regenxbio RGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $76.6M | Buy |
6,397,440
+614,632
| +11% | +$5.1M | ﹤0.01% | 2384 |
|
|
2026
Q1 | $48.5M | Buy |
5,782,808
+25,997
| +0.5% | +$273K | ﹤0.01% | 2521 |
|
|
2025
Q4 | $82.9M | Sell |
5,756,811
-614,082
| -10% | -$7.65M | ﹤0.01% | 2223 |
|
|
2025
Q3 | $61.5M | Sell |
6,370,893
-388,200
| -6% | -$3.43M | ﹤0.01% | 2381 |
|
|
2025
Q2 | $55.5M | Buy |
6,759,093
+1,304,573
| +24% | +$10.9M | ﹤0.01% | 2388 |
|
|
2025
Q1 | $39M | Sell |
5,454,520
-11,582
| -0.2% | -$86.2K | ﹤0.01% | 2511 |
|
|
2024
Q4 | $42.3M | Sell |
5,466,102
-3,378,364
| -38% | -$31.7M | ﹤0.01% | 2561 |
|
|
2024
Q3 | $92.8M | Buy |
8,844,466
+235,128
| +3% | +$2.87M | ﹤0.01% | 2132 |
|
|
2024
Q2 | $101M | Buy |
8,609,338
+1,010,096
| +13% | +$15.7M | ﹤0.01% | 2026 |
|
|
2024
Q1 | $160M | Sell |
7,599,242
-608,306
| -7% | -$10.8M | ﹤0.01% | 1784 |
|
|
2023
Q4 | $147M | Buy |
8,207,548
+181,058
| +2% | +$3.19M | ﹤0.01% | 1850 |
|
|
2023
Q3 | $132M | Sell |
8,026,490
-242,482
| -3% | -$4.39M | ﹤0.01% | 1824 |
|
|
2023
Q2 | $165M | Buy |
8,268,972
+228,182
| +3% | +$4.4M | ﹤0.01% | 1712 |
|
|
2023
Q1 | $152M | Buy |
8,040,790
+1,354,440
| +20% | +$30M | ﹤0.01% | 1749 |
|
|
2022
Q4 | $152M | Buy |
6,686,350
+135,074
| +2% | +$3.05M | ﹤0.01% | 1718 |
|
|
2022
Q3 | $173M | Sell |
6,551,276
-76,847
| -1% | -$2.28M | 0.01% | 1582 |
|
|
2022
Q2 | $164M | Buy |
6,628,123
+39,308
| +0.6% | +$982K | 0.01% | 1677 |
|
|
2022
Q1 | $219M | Buy |
6,588,815
+17,377
| +0.3% | +$483K | 0.01% | 1609 |
|
|
2021
Q4 | $215M | Buy |
6,571,438
+209,635
| +3% | +$7.14M | 0.01% | 1686 |
|
|
2021
Q3 | $267M | Buy |
6,361,803
+160,702
| +3% | +$5.78M | 0.01% | 1504 |
|
|
2021
Q2 | $241M | Sell |
6,201,101
-102,939
| -2% | -$3.68M | 0.01% | 1632 |
|
|
2021
Q1 | $215M | Buy |
6,304,040
+870,668
| +16% | +$37.1M | 0.01% | 1678 |
|
|
2020
Q4 | $246M | Sell |
5,433,372
-223,270
| -4% | -$7.8M | 0.01% | 1457 |
|
|
2020
Q3 | $156M | Buy |
5,656,642
+110,366
| +2% | +$3.6M | 0.01% | 1599 |
|
|
2020
Q2 | $204M | Buy |
5,546,276
+511,587
| +10% | +$19.1M | 0.01% | 1349 |
|
|
2020
Q1 | $163M | Sell |
5,034,689
-194,191
| -4% | -$8.09M | 0.01% | 1313 |
|
|
2019
Q4 | $214M | Buy |
5,228,880
+79,449
| +2% | +$3.14M | 0.01% | 1428 |
|
|
2019
Q3 | $183M | Buy |
5,149,431
+102,328
| +2% | +$4.15M | 0.01% | 1472 |
|
|
2019
Q2 | $259M | Buy |
5,047,103
+169,888
| +3% | +$8.48M | 0.01% | 1232 |
|
|
2019
Q1 | $280M | Buy |
4,877,215
+54,253
| +1% | +$2.69M | 0.01% | 1164 |
|
|
2018
Q4 | $202M | Buy |
4,822,962
+95,917
| +2% | +$5.63M | 0.01% | 1303 |
|
|
2018
Q3 | $357M | Buy |
4,727,045
+508,632
| +12% | +$36.6M | 0.02% | 1028 |
|
|
2018
Q2 | $303M | Buy |
4,218,413
+1,997,447
| +90% | +$95.4M | 0.01% | 1105 |
|
|
2018
Q1 | $66.3M | Sell |
2,220,966
-63,540
| -3% | -$1.85M | ﹤0.01% | 2098 |
|
|
2017
Q4 | $76M | Sell |
2,284,506
-718,533
| -24% | -$21.6M | ﹤0.01% | 2038 |
|
|
2017
Q3 | $99M | Buy |
3,003,039
+160,014
| +6% | +$3.6M | 0.01% | 1862 |
|
|
2017
Q2 | $56.1M | Buy |
2,843,025
+462,434
| +19% | +$8.95M | ﹤0.01% | 2169 |
|
|
2017
Q1 | $45.9M | Buy |
2,380,591
+2,375,549
| +47,115% | +$45.8M | ﹤0.01% | 2276 |
|
|
2016
Q4 | $94K | Sell |
5,042
-1,562
| -24% | -$29.8K | ﹤0.01% | 2578 |
|
|
2016
Q3 | $93K | Buy |
6,604
+1,726
| +35% | +$19K | ﹤0.01% | 2637 |
|
|
2016
Q2 | $39K | Buy |
4,878
+4,775
| +4,636% | +$53K | ﹤0.01% | 3048 |
|
|
2016
Q1 | $1K | Buy |
103
+3
| +3% | +$38 | ﹤0.01% | 3551 |
|
|
2015
Q4 | $2K | Buy |
+100
| New | +$1.99K | ﹤0.01% | 3326 |
|
Other funds holding RGNX
RG
BlackRock's RGNX Position: Q2 2026 in Review
BlackRock increased its Regenxbio (RGNX) stake by 11% in Q2 2026, buying an estimated $5.1M and bringing the position to 6,397,440 shares worth $76.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2384.
BlackRock first reported a position in RGNX in Q4 2015 and has held it in 43 quarters since. The position peaked at $357M in Q3 2018. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.
- BlackRock held 6,397,440 shares of Regenxbio worth $76.6M as of Q2 2026.
- BlackRock bought 614,632 Regenxbio shares in Q2 2026, an estimated $5.1M.
- Regenxbio made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2384 holding.
- BlackRock first reported a position in Regenxbio in Q4 2015 and has held it in 43 quarters since.
- BlackRock's Regenxbio position peaked at $357M in Q3 2018.
- 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.